31JUL

J&J backs Trimtech seed to GBP35.6m

2 min read

12:32UTC

Trimtech Therapeutics extended its seed round to GBP35.6m after Johnson & Johnson Innovation and BGF added $14m and took board seats.

← Back to Humanoid hit $1.35bn on a customer order Jump to analysis ↓

TechnologyDeveloping

Key takeaway

J&J and BGF bought board seats at Trimtech, backing UK biotech that domestic venture is not funding.

Trimtech Therapeutics, a Cambridge biotech, extended its seed round to GBP35.6m after Johnson & Johnson Innovation (JJDC), the US pharmaceutical group's venture arm, and BGF, a UK growth-capital investor, added $14m and both took board seats ¹. The company designs targeted protein degraders, molecules that tag a disease-causing protein for the cell's own disposal system rather than merely blocking it, aimed at neurodegenerative and inflammatory disease.

The extension builds on a GBP25m seed led by Cambridge Innovation Capital in 2025. Strategic pharmaceutical capital, not UK venture, is funding the deep end here.

It is the same pattern as SAP taking a stake in Conduct to hedge its own migration deadline : a corporate investor buys a board seat to watch a technology it may later need, cheaper than building or acquiring it outright. For an early biotech, that visibility cuts both ways, bringing a route to market alongside an incumbent already inside the boardroom.

Deep Analysis

In plain English

Trimtech Therapeutics is a Cambridge company developing medicines that use 'targeted protein degraders', molecules that tag disease-causing proteins so the body's own cells break them down naturally, rather than simply blocking them the way most drugs do. The company has just topped up its earliest funding round to £35.6m after Johnson & Johnson's venture arm and BGF, a UK growth-capital investor, each put in money and took a seat on its board. A board seat gives an investor a formal say in how the company is run, which for a large drugmaker like Johnson & Johnson often signals interest in eventually licensing or buying the technology.

Source Landscape

This story draws on neutral-leaning sources

At £35.6m, Trimtech's extended seed round is unusually large for the stage, closer in size to a typical UK biotech Series A than a first institutional round, reflecting how far corporate venture cheques have grown relative to traditional seed sizes.

Structurally, corporate venture arms like J&J Innovation increasingly substitute for independent Series A leads in UK biotech, which shifts the exit calculus: a founder's most likely acquirer may already sit on the board before the company has even closed its next priced round.

Consensus view: The BioIndustry Association's finance team reads J&J Innovation's board seat as a strategic option on Trimtech's protein-degrader platform, the same corporate playbook SAP used at Conduct in June , where a corporate investor bought oversight and first look rather than pure financial upside.

Counter-view: BGF, the growth-capital co-investor taking its own board seat alongside J&J, frames the move as ordinary governance discipline ahead of a future Series A, arguing not every corporate-adjacent seed extension signals an acquisition path.

Key tension: Whether Trimtech's extended seed is a prelude to J&J licensing or eventually acquiring the platform outright, or a standard governance step before an independent Series A with new lead investors.

Sources:UKTN

Mentions:Laverock Therapeutics →Johnson & Johnson Innovation (JJDC) →BGF →Cambridge Innovation Capital →Cambridge →Conduct →SAP →Trimtech Therapeutics →

First Reported In

Update #10 · AI takes record 44% as UK equity shrinks

UKTN· 4 Jul 2026

Read original →

Causes and effects

Caused by

Conduct takes $60m as SAP buys in

SAP's strategic stake in Conduct set the template of a corporate investor buying board-seat visibility, now repeated with J&J Innovation and BGF in Trimtech.

Occurred 17 Jun 2026

Read story →

This Event

J&J backs Trimtech seed to GBP35.6m

Corporate pharmaceutical capital, not UK venture, is funding the deep end of British biotech and buying boardroom visibility with it.

Different Perspectives

Fubon Financial

Fubon Financial joined Humanoid's Series A on 21 July as a minority financial investor alongside Schaeffler and Bosch, who also hold the customer and manufacturer roles. A pure-play investor from Taipei is pricing a London robot maker on terms two German industrial groups effectively set.

NATO Innovation Fund

The Fund joined Greenjets' £30m Series A on 21 July alongside NSSIF, betting on ducted electric propulsion's civil market to fund a technology with an obvious defence application. It is backing a company that took twenty-one years to reach this stage, on the expectation that certification-cycle timelines reward patient capital over a quick return.

Prime Movers Lab

Prime Movers Lab led Humanoid's Series A on 21 July as the round's only pure financial investor, sharing the cap table with two co-investors who are also the anchor customer and the factory. That leaves the fund's usual arm's-length pricing role diluted by partners with a direct commercial stake in the valuation holding up.

Bosch and Schaeffler

Schaeffler signed what Humanoid calls the industry's largest publicly announced commercial agreement, while Bosch took equity and became contract manufacturer, filling capacity a shrinking combustion supply chain freed. Neither company has disclosed a unit count or an invoice, so their public commitment stops well short of Forbes' 100,000-unit projection.

UK founders raising seed through Series A

A London robotics founder raised $152m this week against a signed industrial customer and a reserved factory, while a Cornwall founder more typically draws a £25,000 loan from a regional fund manager. Both call it British venture funding, but one route runs through Bosch's production line and the other through diligence built for businesses too small for any VC's attention.

EQT

EQT was reported on 3 July to be in advanced talks for a further CuspAI stake on behalf of the EU's Scaleup Europe Fund, but does not appear on the round CuspAI closed. Whether Europe's own sovereign vehicle secured a position, was outbid, or withdrew is unresolved.